Marth C, Mull R, Gastl G, Herold M, Steiner E, Daxenbichler G, Hetzel H, Flener R, Huber C, Dapunt O
Universitätsklinik für Frauenheilkunde Innsbruck.
Geburtshilfe Frauenheilkd. 1989 Nov;49(11):987-91. doi: 10.1055/s-2008-1036852.
Patients with refractory ovarian cancer were treated intra-peritoneally with interferon-gamma. The maximum tolerated dose was achieved at 2 mg/m2. The substance was administered 3 times per week every second week. Interferon-gamma treatment activated locally the macrophages and induced a rise in neopterin urine, serum, and ascites levels. The tumor marker CA-125 showed marked fluctuations of more than 100% during interferon treatment and this was not correlated with neopterin. A flu-like syndrome and especially fatigue were the dose limiting side effects. Two of 3 evaluable patients died on tumor progression whereas one is now 18 months clinically free of disease.